Wockhardt Ltd.

583.55 +27.75 ▲5.0%

28 March 2024, 04:01:00 PM
Volume: 28,767

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.wockhardt.com
Market Cap 8,951.71 Cr.
Enterprise Value(EV) 10,870.71 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -32.72 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 41.54 Trailing Twelve Months Ending 2023-12
Book Value / Share 210.88 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.77 Calculated using Price: 583.55
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 15.34 Cr. 153,400,936 Shares
FaceValue 5
About Wockhardt Ltd.
The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt.

Wockhardt Ltd. Delivery

Delivered Qty
Traded Qty

Wockhardt Ltd. Performance

1 Day
+4.99%
1 Week
+7.24%
1 Month
-3.21%
3 Month
+39.76%
6 Month
+150.61%
1 Year
+286.20%
2 Year
+93.10%
5 Year
+47.44%
10 Year
+39.96%

Wockhardt Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 12.49 7.07 -6.42 -21.81 -11.43 -5.22 -9.92 -7.77 -17.32
Return on Capital Employed (%) 11.25 6.87 -0.31 -5.47 -2.87 -1.11 -5.5 -1.96 -5.88
Return on Assets (%) 5.84 3.25 -2.69 -7.93 -4.01 -1.8 -3.93 -3.71 -8.42

Wockhardt Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 3,715 3,775 3,337 2,852 2,675 2,672 3,376 3,849 3,354 3,125
Non Curr. Liab. 1,872 1,893 3,151 2,089 1,703 1,195 496 261 -22 739
Curr. Liab. 1,773 1,842 1,979 2,692 2,864 3,497 3,121 3,207 3,435 2,685
Minority Int. 144 465 382 346 330 386 383 353 308 307
Equity & Liab. 7,505 7,976 8,849 7,978 7,571 7,749 7,376 7,670 7,075 6,856
Non Curr. Assets 3,983 4,024 4,314 4,599 4,756 5,320 4,951 5,081 4,867 4,819
Curr. Assets 3,522 3,952 4,535 3,380 2,815 2,401 2,281 2,445 1,914 2,037
Misc. Exp. not W/O
Total Assets 7,505 7,976 8,849 7,978 7,571 7,749 7,376 7,670 7,075 6,856

Wockhardt Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 4,482 4,453 4,015 3,937 3,566 2,844 2,708 3,230 2,651 2,776
Other Income 67 66 114 177 21 60 132 20 122 78
Total Income 4,548 4,519 4,129 4,114 3,587 2,904 2,840 3,250 2,773 2,854
Total Expenditure -3,772 -3,959 -4,002 -3,992 -3,604 -2,746 -2,771 -2,932 -2,550 -2,648
PBIDT 776 560 127 122 -17 158 69 318 223 206
Interest -55 -129 -225 -255 -265 -276 -249 -299 -302 -308
Depreciation -145 -142 -149 -150 -164 -224 -246 -247 -251 -221
Taxation -163 -38 21 -26 135 204 271 132 3 -99
Exceptional Items -358 -142 -183 -294 -110
PAT 413 252 -226 -667 -312 -138 -297 -279 -621 -532
Minority Interest -8 -2 30 59 22 -26 -2 35 62 30
Share Associate 1
Other Related Items
Consolidated Net Profit 405 251 -196 -608 -195 -69 686 -244 -559 -502
Adjusted EPS 34 21 -16 -51 -16 -6 57 -17 -39 -35

Wockhardt Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 1,476 355 72 -269 68 183 649 -287 413 153
Cash Fr. Inv. -852 -207 -818 -687 630 95 -156 1,470 -201 -125
Cash Fr. Finan. -601 -76 254 1,254 -769 -776 -680 -1,171 -71 -315
Net Change 23 73 -492 298 -71 -499 -186 12 141 -287
Cash & Cash Eqvt 1,102 1,159 665 964 897 397 219 232 370 90

Wockhardt Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 67.13 67.13 65.75 63.83 60.36 59.31 58.40 55.14 54.93
Public 32.87 32.87 34.25 36.17 39.64 40.69 41.60 44.86 45.07
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 47.32 43.60 47.84 52.77 56.08 65.46 69.08 64.38 74.51

Wockhardt Ltd. Announcements

Thu, 28 Mar 2024
Closure of Trading Window
This is to inform you that pursuant to Companys Code of Conduct for regulating monitoring and reporting trading by designated person the trading window for dealing in the equity shares of the Company will be closed from 1st April 2024 untill 48 hours of declaration of audited Financial Results of the Company for the financial year ended 31st March 2024.
Tue, 26 Mar 2024
Board Meeting Outcome for Outcome Of The Meeting Of The Capital Raising Committee
The Capital Raising Committee of the Company has at its meeting held today i.e. Tuesday 26th March 2024 inter alia: approved the closure of Issue today i.e. Tuesday 26th March 2024 and determined the allocation of 92 85 163 Equity Shares at an issue price of ?517/- per Equity Share (including a premium of ?512/- per Equity Share) which includes a discount of ?27.02/- per Equity Share equivalent to 4.97% to the floor price of ?544.02/- per Equity Share determined as per the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations for the Equity Shares to be allotted to the eligible QIBs in the Issue; approved and adopted the placement document dated 26th March 2024 (Placement Document) in connection with the Issue; and approved and finalized the confirmation of allocation note for sending to such QIBs to whom the allocation of Equity Shares pursuant to the issue is to be confirmed;
Tue, 26 Mar 2024
Announcement under Regulation 30 (LODR)-Allotment
The Capital raising Committee of the Company in its meeting held today i.e. 26th March 2024 approved the issue and allotment of 92 85 163 Equity Shares to eligible QIBs.

Wockhardt Ltd. Technical Scans

Thu, 28 Mar 2024
Close Crossing Last Week High Close Crossing Last Week High
Closing Above Previous High Closing Above Previous High
Making Higher Highs for 3 days Making Higher Highs for 3 days
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Above Last Week High Close Above Last Week High

Wockhardt Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 388,812.23 1,620.50 +0.8%
Cipla Ltd. 120,673.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 102,679.14 6,171.85 +2.0%
Zydus Lifesciences Ltd. 101,151.67 1,007.35 +0.8%
Mankind Pharma Ltd. 92,029.19 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 91,330.58 6,347.35 +1.9%
Divi's Laboratories Ltd. 91,234.91 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.66 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 32.54 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.64 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.01 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 53.29 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.71 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 65.97 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.23 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.66 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.82 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.37 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.36 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.52 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 7.00 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Wockhardt Ltd. FAQ's

What is Wockhardt share price?

Can I buy Wockhardt shares now?

What is the Market Cap of Wockhardt?

What are the key metrics to analyse Wockhardt?

What is the 52 Week High and Low of Wockhardt?

What is the trend of Wockhardt share price?